Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for LARRY EDWARDS´┐Ż
+1.39 (0.85%)
Nov 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 163.21 - 165.89
52 week 122.75 - 165.89
Open 164.20
Vol / Avg. 0.00/957,014.00
Mkt cap 17.81B
P/E 39.20
Div/yield     -
EPS 4.21
Shares 107.85M
Beta 0.76
Inst. own 88%
Feb 1, 2016
Q4 2015 Edwards Lifesciences Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 8, 2015
Edwards Lifesciences Corp 2015 Investor Conference Add to calendar
Nov 10, 2015
Edwards Lifesciences Corp at Credit Suisse Healthcare Conference
Oct 26, 2015
Q3 2015 Edwards Lifesciences Corp Earnings Call - Webcast
Oct 26, 2015
Q3 2015 Edwards Lifesciences Corp Earnings Release
Sep 9, 2015
Edwards Lifesciences Corp at Wells Fargo Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 19.19% 34.92%
Operating margin 24.48% 49.25%
EBITD margin - 23.96%
Return on average assets 12.66% 26.02%
Return on average equity 20.11% 43.42%
Employees 9,100 -
CDP Score - -


1 Edwards Way
IRVINE, CA 92614-5688
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 48
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 53
Bio & Compensation  - Reuters
Catherine M. Szyman Corporate Vice President, Critical Care
Age: 48
Bio & Compensation  - Reuters
Patrick Bruno Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 57
Bio & Compensation  - Reuters
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 58
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Heart Valve Therapy
Age: 49
Bio & Compensation  - Reuters
Martha H. Marsh Director
Age: 66
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 73
Bio & Compensation  - Reuters
Kieran T. Gallahue Independent Director
Age: 51
Bio & Compensation  - Reuters